Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Stevanato Group (NYSE: STVN) announced the construction of a new 6,750 square meter corporate headquarters in Piombino Dese, Italy, aimed at enhancing its production capabilities. The facility will feature production lines for EZ-fill® solutions and serve as a hub for R&D and office space, reflecting the company's ongoing commitment to meet global demand. Construction began in September 2021, with operational production expected by mid-2022. This expansion is part of the company's 2020-2023 Industrial Plan.
Stevanato Group (NYSE: STVN) reported a 37% revenue increase to €214.5 million in Q3 2021, alongside a net profit of €18.6 million and diluted EPS of €0.07. Adjusted net profit rose 39% to €26.4 million, with adjusted diluted EPS at €0.10. The backlog also grew to €834 million. A discretionary bonus of €6.7 million affected net profits, but the company remains optimistic, raising its revenue guidance for the year and projecting adjusted diluted EPS between €0.45 and €0.47.
Stevanato Group S.p.A. (NYSE: STVN) announced it will release its third quarter fiscal 2021 financial results on November 9, 2021, at 6:30 a.m. ET. A conference call will follow at 8:30 a.m. ET, where management will present a slide deck available on their Investor Relations website. The call can be accessed by dialing provided numbers for various countries or via an online broadcast. A replay will be available until November 23, 2021. Founded in 1949, Stevanato is a key provider of drug containment, delivery, and diagnostic solutions for the pharmaceutical industry.
Summary not available.
Stevanato Group (NYSE:STVN) is set to commence construction of a new plant in Fishers, Indiana this month, with plans for completion by 2023. The facility, covering up to 370,000 square feet, represents an investment of approximately $145 million and aims to enhance support for North American pharmaceutical customers. It will produce the company's EZ-Fill® solutions and offer technical after-sales support. Stevanato Group anticipates hiring over 230 new employees by 2025 as part of its expansion strategy.
Stevanato Group (NYSE: STVN) reported second quarter 2021 revenue of €204.0 million, a 26% increase year-on-year, with gross margins rising to 31.2%. Net profit was €34.5 million, equating to €0.14 diluted EPS, including a €4.4 million one-time benefit. Adjusted diluted EPS was €0.12. The company forecasts 2021 revenue between €820 million and €830 million, with adjusted EPS expected to be between €0.43 and €0.47. Strong demand in its biopharmaceutical segment, driven by high-value solutions, contributed to growth. The company raised approximately $453.5 million in its IPO.
Summary not available.
Stevanato Group has priced its initial public offering of 32 million ordinary shares at $21 each, set to trade on the NYSE under the ticker symbol STVN starting July 16, 2021. The offering is anticipated to close on July 20, 2021, subject to standard conditions. Additionally, underwriters have a 30-day option to purchase 4.8 million more shares. The company has also entered into hedging agreements for $420 million and $180 million with Morgan Stanley to address currency exposure from the proceeds.